Scynexis Achieves Merck Milestone

Scynexis, Inc. has received a payment from Merck for achieving a preclinical milestone in the companies’ oncology drug discovery and development collaboration.

“We are pleased to celebrate success in reaching another milestone with our valued partner, Merck,” said Yves Ribeill, Ph.D., president and chief executive officer of Scynexis. “This milestone provides further validation of our long-term relationship with Merck in a number of therapeutic areas through discovery research and innovation.”